Pharming « Terug naar discussie overzicht

Pharming Juli-2021

822 Posts, Pagina: « 1 2 3 4 5 6 ... 37 38 39 40 41 42 | Laatste

Omlaag ↓

HobbyBeurs 28 juli 2021 14:54

Wat een verschil dit forum zeg. Maand geleden pagina's per dag. En nu nauwelijks 1 per week.

LL 30 juli 2021 16:03

Takeda Q1 (April 2021-March 2022) HAE highlights

Revenue
Revenue in Hereditary Angioedema (“HAE”) was 39.0 billion JPY, a year-on-year increase of 0.7 billion JPY, or 1.8%.
Sales of TAKHZYRO were 25.5 billion JPY, an increase of 2.2 billion JPY, or 9.6%, versus the same period of the
previous fiscal year primarily due to new launches including prefilled syringe administration in Europe. Sales of FIRAZYR
decreased by 1.2 billion JPY, or 15.1%, to 6.9 billion JPY, primarily due to the continued impact of generic entrants in the
U.S.

Rare Genetics & Hematology
In Rare Genetics & Hematology, Takeda focuses on hereditary angioedema to transform the treatment paradigm, including
through TAKHZYRO, and on rare hematology and rare metabolic diseases, with the aim to deliver functional cures in a
select group of diseases using novel modalities and platforms.

TAKHZYRO / Generic name: lanadelumab
– In July 2021, Takeda announced the results from two final analyses from the Phase 3 HELP (Hereditary
Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE), which evaluated the long-term safety
(primary endpoint) and efficacy of TAKHZYRO (lanadelumab) 300 mg every two weeks for up to 2.5 years. In the
first analysis, the mean (min, max) reduction in the attack rate compared to baseline observed in the study
population (N=212) was of 87.4 percent (-100; 852.8), and the median reduction was 97.7 percent and patients
received treatment for a mean (standard deviation) duration of 29.6 (8.2) months. At steady state – day 70 to the end
of the treatment period – attack rates were further reduced to a mean of 92.4 percent and a median reduction of 98.2
percent. An additional analysis further suggests TAKHZYRO was a well-tolerated treatment that prevented HAE
attacks over an extended planned 132 week treatment period across specific HAE patient demographic and disease
characteristic subgroups. These data were presented at the 2021 European Academy of Allergy and Clinical
Immunology (EAACI) Hybrid Congress.

Bijlage:

822 Posts, Pagina: « 1 2 3 4 5 6 ... 37 38 39 40 41 42 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	16 apr 2024 13:19
Koers	0,963
Verschil	-0,025 (-2,53%)
Hoog	0,979
Laag	0,956
Volume	3.705.318
Volume gemiddeld	6.407.533
Volume gisteren	5.323.102

Pharming nieuws meer

08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...	2
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...	2
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1
14 feb	Video-update: AEX index, Brunel en Ph...
20 jan	RTW verkleint belang in Pharming	6
09 jan	RTW kleiner in Pharming